2.10 0.00 (0.00%)
After hours: 5:16PM EST
|Bid||2.06 x 1000|
|Ask||2.13 x 800|
|Day's Range||2.0400 - 2.1300|
|52 Week Range||1.9500 - 10.6500|
|Beta (3Y Monthly)||2.42|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||20.17|
The proceeds of the transaction will be utilized to advance ImmuneOncia’s Phase I and II clinical studies of IMC-001, a PD-L1 monoclonal antibody, as well as to support its earlier stage programs. As a result of this financing, ImmuneOncia is expected to be sufficiently funded in preparation for an initial public offering, which is expected to occur in 2021.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! The big shareholder groups in Sorrento Therapeutics,Read More...
NEW YORK, Jan. 31, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
HENDERSON, NV / ACCESSWIRE / January 22, 2019 / The stock market reached a level toward the end of last year where investors and analysts feared a recession. Some of this fear was over a U.S. China trade ...
Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento") announced that the phase 1b study of its non-opioid, afferent nerve ablating drug candidate (resiniferatoxin or “RTX”) for the treatment of pain from osteoarthritis in the knee (intra-articular route of administration) interim data analysis of over 30 patients had positive activity, prompting Sorrento to start planning pivotal studies to start in 2019. Rapid onset of pain relief (day following injection) and sustained clinical benefits (84 days) at the lowest dose tested. The “Phase 1b double-blind study to assess the safety and preliminary efficacy of intra-articular administration of resiniferatoxin versus placebo for the treatment of pain due to moderate to severe osteoarthritis of the knee” was expected to recruit about 40 patients in 5 dose level cohorts or until a maximum tolerated dose (MTD) was reached.
Scilex Pharmaceuticals Inc. (SCILEX), a subsidiary of Sorrento Therapeutics, Inc. (SRNE), today announced that Express Scripts has added ZTlido® (lidocaine topical system) 1.8% to its commercial national formularies representing nearly 30 million lives. ZTLIDO is indicated for relief of pain associated with postherpetic neuralgia (PHN), also referred to as post-shingles pain. “SCILEX worked diligently with Express Scripts to ensure that patients and providers will have access to ZTLIDO, a non-opioid, non-abusive treatment option for post-herpetic neuralgia,” said Mike Sweeting, Vice President, Market Access, Scilex. “Express Scripts’ decision to include ZTLIDO on its national formularies in recognition of the benefit it can provide to patients with post-herpetic neuralgia, or PHN, is an important milestone for SCILEX.
Scilex Pharmaceuticals Inc. (SCILEX), a subsidiary of Sorrento Therapeutics, Inc. (SRNE), today announced that ZTlido® (lidocaine topical system) 1.8% (ZTLIDO) is covered by nearly 100M U.S. insured lives1. ZTLIDO is indicated for relief of pain associated with postherpetic neuralgia (PHN), also referred to as post-shingles pain. “SCILEX has been working closely with pharmacy benefit managers (PBMs) and health plans to help ensure patients and providers have access to ZTLIDO, a non-opioid, non-abusive treatment option for post-herpetic neuralgia,” said Mike Sweeting, Vice President, Market Access, Scilex. ZTLIDO is a topical system product that uses an advanced adhesion technology, providing more efficient lidocaine delivery than Lidoderm® (lidocaine patch 5%)* over a full 12 hours.
Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento") announced today that Dr. Henry Ji, Chairman and CEO, will participate in the East/West CEO conference in San Francisco on January 5th, 2019 at 2:00PM PST at the Four Seasons Hotel San Francisco (prior to the JPM Healthcare Conference). The panel will discuss “Adventures in Financing: Raising Capital in 2018”, with a focus on alternative financing and how innovative biotechnology companies can leverage the value of their assets in commercial and/or development stage to seek significant non-dilutive funding.
The stock market - especially growth stocks - is at an interesting inflection point as we enter the final quarter of 2018. On the one hand, the Standard & Poor's 500-stock index recovered from a tumultuous midyear with a 7% third-quarter gain that marked its best quarterly performance since 2013. On the other, interest-rate worries have sent a quick scare into the markets, and riskier, growth-oriented equities have suffered a bit of a pullback. Still, corporate earnings have impressed, unemployment remains at multi-decade lows and the economy is growing. So as we head into the seasonally strong fourth quarter, the question for anyone who still believes the broader trend is up becomes, "Which stocks are Wall Street analysts singling out as compelling investing opportunities?" We can use TipRanks to pinpoint top growth stocks - as identified by Wall Street's brightest minds - that have significant growth potential. Let's take a closer look at these 10 top picks now: SEE ALSO: The 25 Best Stocks to Buy (According to Hedge Funds)
- Data Presented at PAINWeek® Also Showed ZTlido Was Well-Tolerated and Demonstrated Bioequivalence to Lidoderm® Patch1,2 - Study Results Make Strong Case for ZTlido as Non-Opioid Treatment for Post-Shingles ...
Sorrento Therapeutics Inc (NASDAQ: SRNE ) shares were rallying Monday following the announcement of positive trial results for its osteoarthritis knee pain treatment candidate. In pre-market trading, the ...
NEW YORK, NY / ACCESSWIRE / July 23, 2018 / Ampio Pharmaceuticals and Sorrento Therapeutics both saw big moves in opposite directions on Friday. Ampio Pharmaceuticals, Inc. shares closed up 11.44% on Friday with trading volume roughly three times higher than usual at 2,251,564 shares traded. It was recently revealed that Susquehanna International Group Llp has increased its position in the stock by $57,249.
LONDON, UK / ACCESSWIRE / July 23, 2018/ If you want a free Stock Review on SRNE sign up now at www.wallstequities.com/registration. All you have to do is sign up today for this free limited time offer by clicking the link below.